Comparative Pharmacology
Head-to-head clinical analysis: ACTRON versus DUEXIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTRON versus DUEXIS.
ACTRON vs DUEXIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen (paracetamol) is a non-opioid analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis. It also modulates the endocannabinoid system and serotonergic pathways.
DUEXIS is a combination of ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, and famotidine, a histamine H2-receptor antagonist that decreases gastric acid secretion. Famotidine mitigates the risk of NSAID-induced gastric ulcers.
Oral: 400 mg every 4-6 hours as needed for pain; maximum 1200 mg/day.
One tablet (800 mg ibuprofen/26.6 mg famotidine) orally three times daily.
None Documented
None Documented
Terminal elimination half-life 2-4 hours; prolonged to 6-12 hours in elderly or renal impairment (CrCl <30 mL/min).
Ibuprofen: 2-4 hours (terminal); requires every 6-8 hour dosing. Famotidine: 2.5-3.5 hours (normal renal function); prolonged to 20 hours or more in severe renal impairment (CrCl < 30 mL/min).
Renal: 90% as unchanged drug; biliary/fecal: 10% as metabolites.
Ibuprofen: ~1% unchanged in urine, 14% as conjugated metabolites, remainder as oxidative metabolites; <1% excreted in feces. Famotidine: 65-70% unchanged in urine, 30-35% metabolized hepatic; <10% fecal.
Category C
Category C
NSAID
NSAID/H2 Antagonist Combination